Holen Sie sich die Stockscreener-App
20.03
6.71%
1.26
Schlusskurs vom Vortag:
$18.77
Offen:
$19.74
24-Stunden-Volumen:
728.34K
Relative Volume:
0.88
Marktkapitalisierung:
$2.24B
Einnahmen:
$418.33M
Nettoeinkommen (Verlust:
$-252.07M
KGV:
-8.3458
EPS:
-2.4
Netto-Cashflow:
$-238.84M
1W Leistung:
+11.28%
1M Leistung:
+7.00%
6M Leistung:
-43.78%
1J Leistung:
-30.50%
1-Tages-Spanne:
$19.68
$20.22
1-Wochen-Bereich:
$17.64
$20.22
52-Wochen-Spanne:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Firmenname
Zai Lab Limited Adr
Sektor
Branche
Telefon
862161632588
Adresse
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
20.03 | 2.10B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Eingeleitet | Macquarie | Outperform |
| 2021-10-12 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-04-15 | Eingeleitet | Guggenheim | Buy |
| 2019-07-12 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
| 2019-01-29 | Eingeleitet | Credit Suisse | Outperform |
| 2018-11-21 | Eingeleitet | Jefferies | Buy |
| 2018-06-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Eingeleitet | JP Morgan | Neutral |
| 2017-10-16 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Zai Lab (NASDAQ:ZLAB) Shares Gap UpHere's Why - MarketBeat
Constellation Software Inc. (OTCMKTS:CNSWF) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Analysts Set Kraken Robotics Inc. (CVE:PNG) PT at C$7.13 - Defense World
Brokerages Set Whirlpool Corporation (NYSE:WHR) Target Price at $85.43 - Defense World
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts - Defense World
Everus Construction Group, Inc. (NYSE:ECG) Receives $102.75 Average PT from Brokerages - Defense World
FY2026 Earnings Forecast for PACCAR Issued By Zacks Research - Defense World
Plexus Corp. (NASDAQ:PLXS) Receives $189.20 Average Target Price from Analysts - Defense World
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50 - Defense World
Brokerages Set Medical Properties Trust, Inc. (NYSE:MPW) Price Target at $6.17 - Defense World
Zai Lab Limited's (NASDAQ:ZLAB) Shift From Loss To Profit - Yahoo Finance
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has Lowered Expectations for Zai Lab (NASDAQ:ZLAB) Stock Price - MarketBeat
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
Hilton Food Group (LON:HFG) Insider Purchases £198,900 in Stock - Defense World
Zai Lab (NASDAQ:ZLAB) Reaches New 1-Year Low – Time to Sell? - Defense World
Is UBS’s Global-Innovation Framing Rewriting Zai Lab’s (ZLAB) Long-Term Biopharma Platform Narrative? - Sahm
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform - Finviz
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month LowHere's Why - MarketBeat
8 High Growth Chinese Stocks To Buy - Insider Monkey
Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Zai Lab (NASDAQ:ZLAB) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Short Interest in AiRWA Inc. (NASDAQ:YYAI) Rises By 24.6% - Defense World
Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Drops By 19.8% - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - Defense World
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New AUGTYRO Approval And Pipeline Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Animalcare Group (LON:ANCR) Stock Passes Below 200-Day Moving Average – Here’s What Happened - Defense World
Simply Good Foods (NASDAQ:SMPL) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
How Investors May Respond To Zai Lab (ZLAB) Winning Expanded China Approval For AUGTYRO Cancer Therapy - Sahm
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
UBS gives Zai Lab (ZLAB) a buy rating - MSN
Zai Lab (NASDAQ:ZLAB) Research Coverage Started at UBS Group - Defense World
UBS Gives Zai Lab (ZLAB) a Buy Rating - Insider Monkey
Zai Lab (ZLAB) Is Up 7.9% After First-In-China AUGTYRO Approval Across TRK TKI Settings - Sahm
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - BioSpace
China clears new AUGTYRO use for adults with NTRK‑positive cancers - Stock Titan
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Nah? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 10,787 Shares - Defense World
The Truth About Zai Lab Ltd (ADR): Is This Sleeper Stock About To Explode Or Fade? - AD HOC NEWS
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts - TechStock²
EBITDA per share of Zai Lab Ltd. Sponsored ADR – MUN:1ZL - TradingView — Track All Markets
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025 - ts2.tech
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Sahm
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
Finanzdaten der Zai Lab Limited Adr-Aktie (ZLAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):